The novel coronavirus vaccine developed by the United States-based biotech firm Pfizer and German partner BioNTech has been found to be 95% effective, days after an interim report showed the vaccine to be 90% effective.
Now, as per fresh reports, Pfizer will be quick to apply for regulatory approval for their nRNA-based vaccine candidate, the company said Wednesday, citing fast-track distribution will be imperative to save lives.
According to the company, the final conclusion of the Phase III study involving over 43k people globally for their COVID-19 vaccine candidate meets all the primary efficacy endpoints.
The third-party agency that governed the large-scale trial or the Data Monitoring Committee said it did not note any adverse side-effect from the vaccine except for 3.7 percent of participants experiencing fatigue and 2 percent had a headache.
The analysis found the vaccine efficacy rate has improved from the previous 90% to 95% in participants without or without prior exposure to SARS-CoV-2 infection, when both the cases were measured from 7 days after the second dose.
The result reiterates that Pfizer and BioNTech’s vaccine candidate that makes use of the new-age nRNA-based technology shows real-life potential in inhabiting the novel coronavirus, more than it was though before.
Pfizer’s trial on the efficacy of their vaccine candidate was ongoing even after the interim announcement of the vaccine being fairly capable to prevent COVI-19 made global headlines, sent stocks soaring high, and raised hope for bringing the pandemic under control.
The latest spike in the efficiency of the vaccine dubbed — BNT162b2 — came after 170 participants of the trial were observed, of whom 162 COVID-19 cases were recorded in the placebo group, while only 8 cases were recorded in the BNT162b2 group, Pfizer said.
Results were consistent across the spectrum of race, gender, and ethnicity demographics, but the efficacy of the vaccine dropped a tiny bit of 1% when it came to adults over 65-years-old and more.
“The study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic,” said Dr. Albert Bourla, Pfizer Chairman and CEO.
“We continue to move at the speed of science to compile all the data collected thus far and share with regulators around the world. With hundreds of thousands of people around the globe infected every day, we urgently need to get a safe and effective vaccine to the world.”
Pfizer’s updated report comes shortly after rival vaccine candidate from Moderna Inc. reported their vaccine was evaluated to have an efficacy rate of nearly 95% in the large-scale trial prelim analysis.
Pfizer x BioNTech and Moderna Inc.’s vaccine candidates are being received with great enthusiasm. Vaccines of both the candidates appear to inhabit both mild and severe forms of the novel coronavirus, including delivering over 93% protection to adults in both the case, which is a key parameter for the vaccine’s efficacy.
Although Pfizer’s enthusiasm to get the Emergency Use Approval from the US Food and Drug Administration and elsewhere in Europe and the rest of the world, shipping the extremely temperature-sensitive vaccines will prove to be a huge logistical challenge.
The story has been updated with Pfizer’s official statement and information.